ImmunoPrecise Antibodies Statistics Share Statistics ImmunoPrecise Antibodies has 46.15M
shares outstanding. The number of shares has increased by 63.94%
in one year.
Shares Outstanding 46.15M Shares Change (YoY) 63.94% Shares Change (QoQ) 0% Owned by Institutions (%) 11.97% Shares Floating 40.01M Failed to Deliver (FTD) Shares 1,014 FTD / Avg. Volume 0.04%
Short Selling Information The latest short interest is 495.8K, so 1.08% of the outstanding
shares have been sold short.
Short Interest 495.8K Short % of Shares Out 1.08% Short % of Float 1.09% Short Ratio (days to cover) 1
Valuation Ratios The PE ratio is -0.67 and the forward
PE ratio is -13.47.
ImmunoPrecise Antibodies's PEG ratio is
0.05.
PE Ratio -0.67 Forward PE -13.47 PS Ratio 0.82 Forward PS 3 PB Ratio 0.85 P/FCF Ratio -2.8 PEG Ratio 0.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for ImmunoPrecise Antibodies.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 2.08,
with a Debt / Equity ratio of 0.57.
Current Ratio 2.08 Quick Ratio 1.85 Debt / Equity 0.57 Debt / EBITDA -0.46 Debt / FCF -1.86 Interest Coverage -41.62
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $340.56K Profits Per Employee $-419.92K Employee Count 72 Asset Turnover 0.55 Inventory Turnover 5.24
Taxes Income Tax -4.03M Effective Tax Rate 11.77%
Stock Price Statistics The stock price has increased by 219.87% in the
last 52 weeks. The beta is 0.55, so ImmunoPrecise Antibodies's
price volatility has been higher than the market average.
Beta 0.55 52-Week Price Change 219.87% 50-Day Moving Average 1.33 200-Day Moving Average 0.67 Relative Strength Index (RSI) 60.05 Average Volume (20 Days) 2,511,129
Income Statement In the last 12 months, ImmunoPrecise Antibodies had revenue of 24.52M
and earned -30.23M
in profits. Earnings per share was -0.91.
Revenue 24.52M Gross Profit 13.55M Operating Income -12.2M Net Income -30.23M EBITDA -28.86M EBIT -33.97M Earnings Per Share (EPS) -0.91
Full Income Statement Balance Sheet The company has 10.66M in cash and 13.4M in
debt, giving a net cash position of -2.74M.
Cash & Cash Equivalents 10.66M Total Debt 13.4M Net Cash -2.74M Retained Earnings -128.79M Total Assets 44.44M Working Capital 9.74M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -6.41M
and capital expenditures -799K, giving a free cash flow of -7.21M.
Operating Cash Flow -6.41M Capital Expenditures -799K Free Cash Flow -7.21M FCF Per Share -0.22
Full Cash Flow Statement Margins Gross margin is 55.25%, with operating and profit margins of -49.74% and -123.3%.
Gross Margin 55.25% Operating Margin -49.74% Pretax Margin -139.75% Profit Margin -123.3% EBITDA Margin -117.68% EBIT Margin -49.74% FCF Margin -29.4%
Dividends & Yields IPA does not appear to pay any dividends at this time.
Dividend Per Share n/a Dividend Yield n/a Dividend Growth (YoY) n/a Payout Ratio n/a Earnings Yield n/a FCF Yield n/a
Dividend Details Analyst Forecast The average price target for IPA is $4,
which is 110.5% higher than the current price. The consensus rating is "Buy".
Price Target $4 Price Target Difference 110.5% Analyst Consensus Buy Analyst Count 2
Stock Forecasts Fair Value There are several formulas that can be used to estimate the
intrinsic value of a stock.
Lynch Fair Value n/a Lynch Upside n/a Graham Number n/a Graham Upside n/a
Stock Splits The last stock split was on Nov 23, 2020. It was a
backward
split with a ratio of 1:5.
Last Split Date Nov 23, 2020 Split Type backward Split Ratio 1:5
Scores Altman Z-Score -3.04 Piotroski F-Score 5
